Phaseline

Companies › Accutar Biotechnology

Accutar Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AC676–Phase 1Relapsed/Refractory B-cell Malignancies–
AC699–Phase 1Breast Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05654532AC699Phase 1Breast CancerOncologyMar 2026
NCT05780034AC676Phase 1Relapsed/Refractory B-cell MalignanciesOncologyMar 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.